Eli Lilly and Company (LLY)vsPhreesia Inc (PHR)
LLY
Eli Lilly and Company
$1,208.12
+7.13%
HEALTHCARE · Cap: $1.08T
PHR
Phreesia Inc
$9.13
-1.55%
HEALTHCARE · Cap: $622.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 14478% more annual revenue ($72.25B vs $495.59M). LLY leads profitability with a 35.0% profit margin vs 1.9%. LLY trades at a lower P/E of 42.9x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
PHR
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+72.6%
Fair Value
$45.65
Current Price
$9.13
$36.52 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.6% — below average capital efficiency
1.9% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : PHR
The strongest argument for PHR centers on Debt/Equity, Price/Book. Revenue growth of 12.9% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.9x leaves little room for execution misses.
Bear Case : PHR
The primary concerns for PHR are EPS Growth, Market Cap, Return on Equity. A P/E of 62.9x leaves little room for execution misses. Thin 1.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while PHR is a value play — different risk/reward profiles.
PHR carries more volatility with a beta of 0.88 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 44/100), backed by strong 35.0% margins and 55.5% revenue growth. PHR offers better value entry with a 72.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Phreesia Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Phreesia, Inc. provides integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?